Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Aug 28, 2018

SEC Form 4/A — Form 4/A

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-18

Reporting Person: PERCEPTIVE ADVISORS LLC (Director, 10% Owner)
Reporting Person: PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director, 10% Owner)
Reporting Person: EDELMAN JOSEPH (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-18	Common Stock	P	307648	$21.30	Acquired	307648	Indirect
2018-07-20	Common Stock	C	1880305	—	Acquired	2187953	Indirect
2018-07-20	Common Stock	P	400000	$17.00	Acquired	2587953	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-20	Series B Preferred Stock	$	C	6186205	Disposed		Common Stock (1880305)	Indirect

Footnotes

F1: This Form 4/A is being filed to report the July 18, 2018 purchase and correct the number of shares held by the Master Fund (as defined in Footnote 2).

F2: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

F3: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.